You just read:

U.S. FDA Approves Daiichi Sankyo's Once-Daily SAVAYSA™ (edoxaban) Tablets for Reduction of Stroke Risk in Non-Valvular Atrial Fibrillation and for the Treatment of Venous Thromboembolism

News provided by

Daiichi Sankyo

Jan 08, 2015, 10:03 ET